0.1700GBP-8.11%Mkt Cap: 5.69M $P/E: —1d ago
Nuformix plc, together with its subsidiary, Nuformix Technologies Limited, operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. The compan…
Industry Peers
Biotechnology$130.23BUSDP/E 32.1
$139.84BUSDP/E 32.2
$85.11BUSDP/E 20.4
$69.62BUSD
$61.34BUSDP/E 39.8
$45.95BUSDP/E 19.6
$46.01BUSD
$41.76BUSDP/E 66.2
$35.67BUSDP/E 33.2
$32.46BUSDP/E 42.3
$28.53BUSD
$26.14BUSD
$25.79BUSDP/E 16.2
$20.83BUSDP/E 26.3
$19.26BUSDP/E 26.6
$17.03BUSDP/E 20.0
$16.41BUSD
$13.48BUSDP/E 17.1
$13.42BUSDP/E 187.4
$12.87BUSDP/E 264.5
Key Statistics
Company
Market Cap5.69M $
Enterprise Value4.50M $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-837.01K $
Revenue/Share—
Last Price0.1700 GBP
Fiscal Year EndSep 2025
MR QuarterMar 2026
Employees3
CountryGB
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG—
EV/EBITDA-5.82
EV/Revenue—
P/S—
P/B1.76
EPS (TTM)0.00
EPS (Forward)—
52W Range
0.072020% of range0.5550
52W High0.5550 GBP
52W Low0.0720 GBP
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-86.44%
ROA-64.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-788.30K $
CapEx (TTM)—
FCF Margin—
FCF Yield-8.80%
Net Debt-1.19M $
Net Debt/EBITDA1.55
Balance Sheet
Debt/Equity—
Current Ratio4.32
Quick Ratio4.32
Book Value/Sh0.0010 GBP
Cash/Share0.0000 GBP
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 GBP
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.61B
Float2.50B
Insiders5.37%
Institutions0.07%
Technical
SMA 500.1662 (+2.3%)
SMA 2000.2112 (-19.5%)
Beta1.52
S&P 52W Chg18.16%
Avg Vol (30d)25.33M
Avg Vol (10d)50.43M
Technical Indicators
RSI (14)55.9
MACD-0.0031
MACD Signal-0.0073
MACD Hist.+0.0042
BB Upper0.1837 GBP
BB Middle0.1503 GBP
BB Lower0.1169 GBP
BB Width44.44%
ATR (14)0.0239 GBP
Vol Ratio (20d)1.52x